Skip To Main Content
Zain Chagla on Muck Rack

Zain Chagla

As seen in: MSN Canada, Yahoo Canada, The Conversation, The Globe and Mail, The Toronto Star, JAMA Network, Medscape, National Post, Medical Xpress, AlterNet and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Zain

Contact Zain, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Variability in Hospital-Onset Bacteremia in Ontario

|
By Xuejiao Wei, Nick Daneman, Kevin Brown, Fizza Manzoor, Dominik Mertz, Zain Chagla, Jennifer A. Flemming, Sudeep S. Gill, Anthony D Bai, Olivier Bedard-Lapointe, Mona Golmohammadzadeh
| JAMA Network Verified
Introduction Hospital-onset bacteremia and fungemia (HOB) has emerged as a potential hospital-level quality metric for health care–associated infections.1 It is commonly defined as a positive blood culture for bacterial or fungal organisms obtained on or after hospital day 4, with the day of admission defined as hospital day 1.1 Compared with traditional infection prevention and control metrics, HOB offers several practical advantages.
Open in Who Shared Issue with article?

In outpatients with COVID-19 during Omicron variant circulation, molnupiravir and nirmatrelvir–ritonavir improved outcomes | Annals of Internal Medicine

|
By Zain Chagla
| Annals of Internal Medicine Verified
• None Butler CC, Hobbs FDR, Gbinigie OA, et al; PANORAMIC Trial Collaborative Group. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2023;401:281-293.
Open in Who Shared Issue with article?

Guide to Novavax’s Recombinant Protein Vaccine with Adjuvant

|
By Zain Chagla
| Medscape Verified
close Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. In the constantly evolving landscape of COVID-19, a multifaceted approach to fighting SARS-CoV-2 is critical. As new variants continue to challenge our response strategies, Novavax’s recombinant protein, adjuvanted vaccine has an important place in the protection paradigm.
Open in Who Shared Issue with article?
See all 80 articles